Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01949324 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel
A Phase 2 study, sponsored by Neurotech Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT01949324: Completed Phase 2 study, sponsored by Neurotech Pharmaceuticals.
NCT01949324 is a Phase 2 study that has completed, run by Neurotech Pharmaceuticals. The registered enrollment target is 67 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01949324, a Phase 2 study, has completed, sponsored by Neurotech Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
This study is a phase 2, randomized, multi-center, single-masked study to evaluate the efficacy and safety of the NT-501 implants in participants with Mactel.
Primary Outcome
Change in the ellipsoid zone (area of IS/OS loss) from baseline to month 24 as measured by en face imaging by SDOCT in study eye(s)
Interventions
- PROCEDURE Sham procedure
- BIOLOGICAL Ciliary neurotrophic factor (CNTF)
- DEVICE NT-501 Implant
- PROCEDURE NT-501 Implant procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2014-04 |
| Est. Completion | 2017-05-22 |
| Phase | Phase 2 |
What the finished NCT01949324 record still lists
NCT01949324 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 4 interventions - of which Sham procedure is the first listed.
NCT01949324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01949324 about?
NCT01949324 is a clinical study titled "A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel". This study is a phase 2, randomized, multi-center, single-masked study to evaluate the efficacy and safety of the NT-501 implants in participants with Mactel.
What is the current status of trial NCT01949324?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2014-04. Estimated completion is 2017-05-22.
What interventions are being tested in trial NCT01949324?
The interventions under investigation include: Sham procedure (PROCEDURE), Ciliary neurotrophic factor (CNTF) (BIOLOGICAL), NT-501 Implant (DEVICE), NT-501 Implant procedure (PROCEDURE).
Who is sponsoring clinical trial NCT01949324?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01949324's enrollment target sits among peer trials
67 974th of 2000 higher than 1,026 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia